(Q38017504)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683426%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683426%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683426%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Roy A Jensen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683426%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

9 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683426%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

published in

Translational Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683426%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

160

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683426%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683426%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

178-197

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683426%20AND%20SRC:MED&resulttype=core&format=json

Susceptibility pathways in Fanconi's anemia and breast cancer

4 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Fanconi anemia in Ashkenazi Jews

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Cancer in Fanconi anemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

A 20-year perspective on the International Fanconi Anemia Registry (IFAR).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Hematopoietic stem cell transplantation in childhood inherited bone marrow failure syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Cancer risks in BRCA2 mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Hereditary breast cancer in Jews

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Repeated observation of breast tumor subtypes in independent gene expression data sets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Epidemiology of Health Disparities in Relation to the Biology of Estrogen Receptor–Negative Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

BRCA1 dysfunction in sporadic basal-like breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

BRCA1 functions as a breast stem cell regulator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Susceptibility of Fanconi's anaemia fibroblasts to chromosome damage by carcinogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Improved survival in women with BRCA-associated ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

PARP inhibitors stumble in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

BRCA-associated breast cancer in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Familial invasive breast cancers: worse outcome related to BRCA1 mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Prognosis of BRCA-associated breast cancer: a summary of evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early- and late-onset breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Regulation of DNA double-strand break repair pathway choice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

DNA interstrand crosslink repair and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations ofBRCA1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

BRCA1 promoter methylation predicts adverse ovarian cancer prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

BRCA1 mutations do not increase prostate cancer risk: results from a meta-analysis including new data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Immunohistochemical expression of BRCA1 and lethal prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Cancer risks in BRCA2 families: estimates for sites other than breast and ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Prostate Cancer Progression and Survival in BRCA2 Mutation Carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Transplantation for Fanconi's anaemia: long-term follow-up of fifty patients transplanted from a sibling donor after low-dose cyclophosphamide and thoraco-abdominal irradiation for conditioning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Kinetics of H2AX phosphorylation after exposure to cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Biomarkers and mechanisms of FANCD2 function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Basal-like breast cancer and the BRCA1 phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Resistance to therapy caused by intragenic deletion in BRCA2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

A novel cell-free screen identifies a potent inhibitor of the Fanconi anemia pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Solution Structures of a DNA Dodecamer Duplex with and without a Cisplatin 1,2-d(GG) Intrastrand Cross-Link: Comparison with the Same DNA Duplex Containing an Oxaliplatin 1,2-d(GG) Intrastrand Cross-Link † , ‡

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.022

10.1016/J.TRSL.2012.01.022

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22683426%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference